意大利子宫肉瘤管理共识会议:S.I.G.O. 推荐意见
该共识由意大利妇产科学会(S.I.G.O.)牵头制定,针对罕见且异质性高的子宫肉瘤,汇总了手术、术后辅助治疗、晚期化疗及放疗等推荐。核心推荐包括:早期行子宫切除+双侧输卵管卵巢切除、避免粉碎术、淋巴结清扫仅用于大块淋巴结者;晚期可先行化疗或激素治疗再考虑减瘤手术;治疗应集中在转诊中心多学科管理。
要点
- 早期子宫肉瘤行子宫切除+双侧输卵管卵巢切除,避免粉碎术,无大块淋巴结者不行淋巴结清扫。
- 早期低级别子宫内膜间质肉瘤及无肉瘤过度生长的腺肉瘤可根据激素受体表达给予辅助激素治疗。
- 晚期腹部病变可先化疗(低级别ESS/腺肉瘤可激素治疗),有反应者再考虑减瘤手术。
核心结论
- 子宫肉瘤的治疗应集中在转诊中心并以多学科模式管理。
研究设计与样本
- 意大利共识会议,由S.I.G.O.牵头制定,针对子宫肉瘤的治疗与医疗质量提供推荐。
主要发现
- 早期子宫肉瘤根据绝经状态和组织学行子宫切除+双侧输卵管卵巢切除,无大块淋巴结者不行淋巴结清扫,必须避免粉碎术。
- 早期低级别子宫内膜间质肉瘤及无肉瘤过度生长的腺肉瘤可根据激素受体表达给予辅助激素治疗。
- 晚期腹部病变可先化疗(低级别ESS/腺肉瘤可激素治疗)以测试敏感性,临床和影像学缓解者可考虑减瘤手术。
- 化疗方案基于蒽环类±异环磷酰胺或达卡巴嗪;姑息放疗用于症状控制,立体定向放疗可用于最多五个孤立转移灶。
关键数值与推荐
- 早期术后管理为观察,部分高危患者可考虑化疗。
- 特定病例可考虑外照射放疗±近距离放疗以仅提高局部控制。
- 化疗方案为蒽环类±异环磷酰胺或达卡巴嗪。
- 立体定向放疗可用于最多五个孤立转移灶。
临床怎么用
- 早期子宫肉瘤应避免粉碎术,无大块淋巴结者不行淋巴结清扫。
- 早期低级别ESS及无肉瘤过度生长的腺肉瘤应检测激素受体以指导辅助激素治疗。
- 晚期腹部病变可先全身治疗评估敏感性,缓解后再考虑减瘤手术。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Uterine sarcomas are very rare tumours with different histotypes, molecular features and clinical outcomes; therefore, it is difficult to carry out prospective clinical trials, and this often results in heterogeneous management of patients in the clinical practice. AIM: We planned to set up an Italian consensus conference on these diseases in order to provide recommendations on treatments and quality of care in our country. RESULTS: Early-stage uterine sarcomas are managed by hysterectomy + bilateral salpingo-oophorectomy according to menopausal status and histology; lymphadenectomy is not indicated in patients without bulky nodes, and morcellation must be avoided. The postoperative management is represented by observation, even though chemotherapy can be considered in some high-risk patients. In early-stage low-grade endometrial stromal sarcoma and adenosarcomas without sarcomatous overgrowth, hormonal adjuvant treatment can be offered based on hormone receptor expression. In selected cases, external beam radiotherapy ± brachytherapy can be considered to increase local control only. Patients with advanced disease involving the abdomen can be offered primary chemotherapy (or hormonal therapy in the case of low-grade endometrial stromal sarcoma and adenosarcoma without sarcomatous overgrowth), even if potentially resectable in the absence of residual disease in order to test the chemosensitivity (or hormonosensitivity); debulking surgery can be considered in patients with clinical and radiological response. Chemotherapy is based on anthracyclines ± ifosfamide or dacarbazine. Palliative radiotherapy can be offered for symptom control, and stereotactic radiotherapy can be used for up to five isolated metastatic lesions. CONCLUSIONS: Treatment of uterine sarcoma should be centralised at referral centres and managed in a multidisciplinary setting.
引用
- Ferrandina G, Aristei C, Biondetti PR, et al. Italian consensus conference on management of uterine sarcomas on behalf of S.I.G.O. (Societa' italiana di Ginecologia E Ostetricia). Eur J Cancer. 2020. PMID: 32992154. doi:10.1016/j.ejca.2020.08.016
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。